COVID‐19: Thrombosis, thromboinflammation, and anticoagulation considerations
Autor: | Jerrold H. Levy, Jean M. Connors, Kamrouz Ghadimi, Kristen M Corey, Lyra B. Olson, Toshiaki Iba |
---|---|
Rok vydání: | 2021 |
Předmět: |
Vasculitis
medicine.medical_specialty Coronavirus disease 2019 (COVID-19) medicine.medical_treatment Clinical Biochemistry Reviews Review Lung injury Thrombophilia coagulopathy Pregnancy Thromboembolism Fibrinolysis medicine Coagulopathy Humans Pregnancy Complications Infectious International Society for Laboratory Hematology 2021 Education Issue Child Intensive care medicine Lung Pandemics disseminated intravascular coagulation thrombosis Covid‐19 Disseminated intravascular coagulation anticoagulant therapy SARS-CoV-2 business.industry Biochemistry (medical) Anticoagulants COVID-19 Hematology General Medicine medicine.disease Thrombosis endothelial cell Female Endothelium Vascular business Forecasting |
Zdroj: | International Journal of Laboratory Hematology |
ISSN: | 1751-553X 1751-5521 |
DOI: | 10.1111/ijlh.13500 |
Popis: | Vascular endothelial injury is a hallmark of acute infection at both the microvascular and macrovascular levels. The hallmark of SARS‐CoV‐2 infection is the current COVID‐19 clinical sequelae of the pathophysiologic responses of hypercoagulability and thromboinflammation associated with acute infection. The acute lung injury that initially occurs in COVID‐19 results from vascular and endothelial damage from viral injury and pathophysiologic responses that produce the COVID‐19–associated coagulopathy. Clinicians should continue to focus on the vascular endothelial injury that occurs and evaluate potential therapeutic interventions that may benefit those with new infections during the current pandemic as they may also be of benefit for future pathogens that generate similar thromboinflammatory responses. The current Accelerating COVID‐19 Therapeutic Interventions and Vaccines (ACTIV) studies are important projects that will further define our management strategies. At the time of writing this report, two mRNA vaccines are now being distributed and will hopefully have a major impact on slowing the global spread and subsequent thromboinflammatory injury we see clinically in critically ill patients. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |